Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
10.83
+1.30 (13.64%)
At close: May 12, 2025, 4:00 PM
10.29
-0.54 (-4.99%)
After-hours: May 12, 2025, 4:12 PM EDT
Gyre Therapeutics Revenue
Gyre Therapeutics had revenue of $22.06M in the quarter ending March 31, 2025, a decrease of -18.82%. This brings the company's revenue in the last twelve months to $100.64M, down -13.01% year-over-year. In the year 2024, Gyre Therapeutics had annual revenue of $105.76M, down -6.78%.
Revenue (ttm)
$100.64M
Revenue Growth
-13.01%
P/S Ratio
9.24
Revenue / Employee
$173,822
Employees
579
Market Cap
954.13M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 105.76M | -7.69M | -6.78% |
Dec 31, 2023 | 113.45M | 11.16M | 10.91% |
Dec 31, 2022 | 102.29M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGYRE News
- 3 days ago - Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications - GlobeNewsWire
- 6 weeks ago - Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology - GlobeNewsWire
- 2 months ago - Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 6 months ago - Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update - GlobeNewsWire
- 7 months ago - Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis - GlobeNewsWire
- 7 months ago - Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference - GlobeNewsWire
- 9 months ago - Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update - GlobeNewsWire